EyeGene
EYEGENE Inc. is a biotechnology company dedicated to developing innovative biopharmaceuticals, vaccines, and diagnostic systems for the treatment and prevention of age-related diseases. The company utilizes platform technologies such as immune adjuvants and is actively involved in research and development of vaccines for diseases like diabetic retinopathy, herpes zoster, COVID-19, and others. With a focus on cutting-edge research, EYEGENE aims to be a global leader in biotech innovation.
Industries
Nr. of Employees
medium (51-250)
Products
Therapeutic candidate for diabetic retinopathy (pericyte-recruiting biologic)
Biologic therapeutic developed to recruit pericytes to damaged retinal microvasculature to reduce vascular leakage and stabilize ischemic blood vessels; progressed through preclinical studies and Phase 1/2a clinical trials in multiple jurisdictions.
Wound-healing biologic candidate (decorin-based)
Therapeutic protein candidate for pressure ulcers and wound healing with in vivo models showing accelerated epidermis and dermis regeneration; has progressed through preclinical toxicology and Phase 1/2 clinical steps.
Myocardial ischemia / reperfusion biologic candidate
Therapeutic development targeting microvascular damage associated with myocardial ischemia and reperfusion injury; supported by preclinical efficacy and progressed into phased clinical trials.
mRNA-based COVID-19 vaccine candidate
mRNA vaccine candidate with in vivo evidence of effective mRNA delivery and expression using a non-LNP delivery system, cross-reactivity against multiple virus variants in preclinical studies, and a freeze-dried formulation demonstrating refrigerated stability for defined periods.
Herpes zoster vaccine candidate
Vaccine candidate for herpes zoster with activities including cell line development, adjuvant screening, MCB production process development and completion of Phase 1 clinical studies.
Wholesale pharmaceutical product: hyaluronidase injectable formulations
Distribution of hyaluronidase enzyme injectable preparations in multiple vial sizes and potencies for clinical use to enhance subcutaneous or intramuscular permeation and to promote resorption of excess tissue fluid.
Therapeutic candidate for diabetic retinopathy (pericyte-recruiting biologic)
Biologic therapeutic developed to recruit pericytes to damaged retinal microvasculature to reduce vascular leakage and stabilize ischemic blood vessels; progressed through preclinical studies and Phase 1/2a clinical trials in multiple jurisdictions.
Wound-healing biologic candidate (decorin-based)
Therapeutic protein candidate for pressure ulcers and wound healing with in vivo models showing accelerated epidermis and dermis regeneration; has progressed through preclinical toxicology and Phase 1/2 clinical steps.
Myocardial ischemia / reperfusion biologic candidate
Therapeutic development targeting microvascular damage associated with myocardial ischemia and reperfusion injury; supported by preclinical efficacy and progressed into phased clinical trials.
mRNA-based COVID-19 vaccine candidate
mRNA vaccine candidate with in vivo evidence of effective mRNA delivery and expression using a non-LNP delivery system, cross-reactivity against multiple virus variants in preclinical studies, and a freeze-dried formulation demonstrating refrigerated stability for defined periods.
Herpes zoster vaccine candidate
Vaccine candidate for herpes zoster with activities including cell line development, adjuvant screening, MCB production process development and completion of Phase 1 clinical studies.
Wholesale pharmaceutical product: hyaluronidase injectable formulations
Distribution of hyaluronidase enzyme injectable preparations in multiple vial sizes and potencies for clinical use to enhance subcutaneous or intramuscular permeation and to promote resorption of excess tissue fluid.
Services
Bio-IT systems implementation (EDMS, EQMS, LIMS, ELN)
Provision and integration of regulated document and laboratory management systems for pharmaceutical and biotech firms; includes supply contracts and system implementation.
Bio-IT systems implementation (EDMS, EQMS, LIMS, ELN)
Provision and integration of regulated document and laboratory management systems for pharmaceutical and biotech firms; includes supply contracts and system implementation.
Expertise Areas
- Vaccine development (preventive and therapeutic)
- mRNA vaccine formulation and delivery
- Biologic therapeutic development (recombinant proteins)
- Proteomics-informed target discovery and informatics
Key Technologies
- mRNA vaccine platforms
- Non-LNP mRNA delivery systems
- Immune adjuvant platforms
- Conjugate vaccine platforms